title: Treatment of metastatic renal cell carcinoma with recombinant interleukin-2 in combination with vinblastine or lymphokine-activated killer cells.
abstract: Fifty patients with metastatic renal cell carcinoma were treated with recombinant interleukin-2 alone or in combination with the antitumor drug vinblastine or lymphokine-activated killer cells. Of 34 evaluable patients treated with intravenous bolus interleukin-2, 1 (3%) had a partial response. Vinblastine increased myelotoxicity but did not enhance response to interleukin-2 in 15 of these patients. Two partial responses were observed among 15 patients treated with lymphokine-activated killer cells in addition to interleukin-2. In 1 patient biopsy documented complete resolution of hepatic metastases lasting for 1 year was observed. All responders had undergone previous nephrectomy and none had multiple sites of metastatic disease. Toxicity was significant and caused termination of therapy in 40% of the patients. Biological therapy using interleukin-2 can result in prolonged responses in renal cell cancer but future trials should be directed at lessening toxicity.
authors.affiliation: Department of Urology, University of Oklahoma Health Science Center, Oklahoma City 73104.
authors.forename: J P
authors.initials: JP
authors.lastname: Kuebler
authors.forename: R P
authors.initials: RP
authors.lastname: Whitehead
authors.forename: D L
authors.initials: DL
authors.lastname: Ward
authors.forename: G P
authors.initials: GP
authors.lastname: Hemstreet
authors.forename: E C
authors.initials: EC
authors.lastname: Bradley
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000556:secondary* / Q000628:therapy*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D016219:Immunotherapy, Adoptive; D007376:Interleukin-2 / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000473:pathology / Q000628:therapy*; D015979:Killer Cells, Lymphokine-Activated; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D014747:Vinblastine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D007376:Interleukin-2; D011994:Recombinant Proteins; D014747:Vinblastine